Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

More Documents

JN0003

Sigma-Aldrich

Ridogrel

≥98% (HPLC)

Synonym(s):

5-[(E)-[3-pyridyl-[3-(trifluoromethyl)phenyl]methylene]amino]oxypentanoic acid, R 68070, R068070

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H17F3N2O3
CAS Number:
110140-89-1
Molecular Weight:
366.33
MDL number:
MFCD00873577
UNSPSC Code:
12352200
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

room temp

SMILES string

O=C(O)CCCCO/N=C(C1=CC=CN=C1)\C2=CC=CC(C(F)(F)F)=C2

InChI

1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17-

InChI key

GLLPUTYLZIKEGF-QJOMJCCJSA-N

Biochem/physiol Actions

Ridogrel is an orally active, potent and specific combined thromboxane synthase inhibitor and thromboxane A2 receptor ( thromboxane/prostaglandin endoperoxide receptor) antagonist. Ridogrel is a potent antiplatelet agent.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J J Auwerda et al.
European journal of gastroenterology & hepatology, 13(4), 397-400 (2001-05-08)
To evaluate the effect of Ridogrel enemas (Janssen Research Foundation, Beerse, Belgium) on disease activity and mucosal inflammatory mediators in patients with active left-sided ulcerative colitis. Eleven patients with active left-sided ulcerative colitis were evaluated in an open non-placebo-controlled pilot
E Carty et al.
Alimentary pharmacology & therapeutics, 14(6), 807-817 (2000-06-10)
Thromboxanes, prostaglandins, reactive oxygen metabolites and pro-inflammatory cytokines are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthesis inhibitor and receptor blocker, may have therapeutic benefits in ulcerative colitis. To investigate the anti-inflammatory profile

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service